Purpose of review
The treatment of small, low-risk papillary thyroid carcinoma
has undergone a paradigm shift, with many tumors now initially treated with active surveillance
rather than upfront surgery. Further studies on patients enrolled in active surveillance
have refined our knowledge of the clinical behavior of papillary thyroid microcarcinomas.
This article summarizes the major conclusions of landmark trials that launched active surveillance
as a viable treatment option for selected patients. We discuss patient factors such as age and tumor size, the assessment of candidates for active surveillance
, barriers to acceptance of active surveillance
, quality of life issues, and economic considerations.
Summary Active Surveillance
is a viable first-line treatment option for select papillary microcarcinomas.